Life science AI and machine learning Market Size, Share and Trends 2026 to 2035

What is the Life Science AI and Machine Learning Market Size?

The global life science AI and machine learning market is growing rapidly as AI-driven tools transform drug discovery, diagnostics, and precision medicine.The market for life science AI and machine learning is driven by precision research needs, automation, advanced diagnostics, and the rising adoption of intelligent drug-discovery and clinical decision-support systems.

Market Highlights

• North America led the life science AI and machine learning market with a 38% market share in 2025.
• The Asia Pacific is expected to expand the fastest CAGR between 2026 and 2035.
• By product type, the AI analytics platforms segment captured around 35% of market share in 2025.
• By product type, the machine learning software tools segment is growing at the highest CAGR between 2026 and 2035.
• By deployment type supported, the on-premise segment held more than 50% of the market share in 2025.
• By deployment type supported, the cloud-based segment is growing at a strongt CAGR between 2026 and 2035.
• By application, the drug discovery & development segment contributed the 40% of the market share in 2025.
• By application, the genomics & precision medicine segment is expanding at the highest CAGR between 2026 and 2035.
• By technology/mode of action, the machine learning algorithms segment captured 35% of market share in 2025.
• By technology/mode of action, the deep learning / neural networks segment is expected to expand at the highest CAGR between 2026 and 2035.
• By end-user, the pharmaceutical & biotech companies segment held a 45% share in the life science AI and machine learning market during 2025.
• By end-user, the CROs / clinical research organizations segment is poised to grow at a notable CAGR between 2026 and 2035.

Life science AI and machine learning Market Explained: Tools, Platforms, and Data-Driven Research

The life science AI and machine learning market encompasses advanced computational technologies designed to analyse complex biological data, accelerate drug discovery, enhance clinical decision-making, and optimize research workflows across biotechnology , pharmaceuticals, genomics , proteomics, medical imaging , and healthcare analytics.

AI/machine learning growth is projected to continue at exponential rates as more and more organisations leverage AI/machine learning tools to shorten drug development cycles, identify biomarkers more quickly, develop precision-based diagnostics, and create more efficient laboratory workflows. The massive amounts of genomic data being generated, along with an investment push in digital health infrastructure and the ongoing demand for improved predictive analytics , will further propel the adoption of these technologies in the market.

Pharmaceutical companies are increasingly utilising AI/ machine learning -enabled software solutions to reduce their R&D timelines, while providers are utilising these models to improve how they identify patients at risk of disease and optimise treatment plans. Growth in regulatory support for digital health , along with advancements in transparency around ML model architecture, will reinforce growth in the life sciences ecosystem worldwide.

Artificial Intelligence's Contribution to the Future of Life Sciences Innovations

The use of AI and machine learning to improve how research, diagnostics and drug development are conducted is seeing significant interest in the life sciences, expected to lead to several breakthroughs and change the way these activities are conducted in the life sciences industry. Deep learning techniques can evaluate biological data (e.g., genomic sequences, imaging, proteomics ) at an unprecedented level of accuracy and assist researchers in identifying markers for disease and predicting treatment response. Drug discovery is being transformed through AI systems by automating molecule screening, improving predictor models of drug-target interactions, and providing tools to design more effective clinical trial parameters and protocols to speed up the drug discovery process.

Cloud-based AI systems support collaborative efforts between researchers to integrate laboratory workflows, automate and streamline what was once done manually and create a more reproducible science environment. As a result of all of the technologies described above, researchers can make faster and better decisions about a patient's therapy, develop more specialized therapies, and maintain an organized laboratory environment with better operations.

• As of December 2025, Excelsior Sciences raised USD 95 million to build out its AI-based drug development engine, which allows for accelerated small-molecule drug discovery by enabling reduced manual screening times.

Artificial Intelligence in Life Sciences: The Next Frontier for Research and Development

• Reimagining Drug Discovery: AI is enabling researchers to accelerate the process of early discovery by intelligently identifying targets, quickly screening compounds for candidates, and using generative de novo design to design new molecules. Through this technology, researchers can now create breakthrough molecules much faster and with better accuracy than ever before.
• Revolutionizing Value of Pre-Clinical Research: By providing researchers with accurate safety assessment information for their molecules before they reach the clinic, AI-generated preclinical simulations and Integrated pharmacokinetic/pharmacodynamics models, as well as predictive toxicity modelling tools, provide critical insights that allow them to evaluate potential compounds more efficiently and effectively, therefore, reducing the need for time-consuming and costly trial-and-error experiments.
• Enhanced Clinical Research Efficiency: AI-enhanced trial recruitment and patient adherence tracking capabilities, as well as real-time data capture capabilities provided through machine learning, allow researchers to improve their quality of clinical results by being smarter, faster, and more reliable.
• Drug Development and Manufacturing: AI provides more efficient and cost-effective ways to control processes, monitor the manufacturing process through predictive modes, and design optimized production models.
• Broader Applications across Life Science: Comprehensive AI platforms are able to manage all aspects of data governance, automate workflow, tag and harmonize all types of data seamlessly, as well as classify and search for powerful capabilities from any data source or platform within the life sciences ecosystem.

Market Scope

Life science AI and machine learning Market Segment Insights

[[segment_insights]]

Life science AI and machine learning Market Regional Insights

[[regional_insights]]

Top Key in Players' Life science AI and machine learning Market and their Offerings

• IBM Watson Health
• Google DeepMind / Google Life Sciences (Verily)
• Microsoft Healthcare AI
• NVIDIA Corporation
• Amazon Web Services (AWS) AI/ML for Life Sciences
• SAS Institute
• IQVIA
• Thermo Fisher Scientific
• Illumina AI Platforms
• Roche Diagnostics AI Solutions
• Philips Healthcare AI
• Siemens Healthineers
• GE Healthcare
• Schrödinger, Inc.
• Exscientia
• BenchSci
• PathAI
• Tempus Labs
• Insilico Medicine
• BioNTech AI-Driven Research Platforms

Life science AI and machine learning Market Segments Covered in the Report

[[segment_covered]]